ACUSENSUS LIMITED (ACE)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ACE

ACE - ACUSENSUS LIMITED

FNArena Sector : Transportation & Logistics
Year End: June
GICS Industry Group : Software & Services
Debt/EBITDA: 2.52
Index: ALL-TECH

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.80

26 Feb
2026

0.095

OPEN

$1.75

5.57%

HIGH

$1.85

170,754

LOW

$1.75

TARGET
$2.30 27.8% upside
OTHER COMPANIES IN THE SAME SECTOR
AIZ . AQZ . AVD . AZJ . BWN . BXB . CLX . ERD . FRW . KLS . KSC . LAU . NTD . QAN . QUB . SPZ . SST . THL . WTC .
FNARENA'S MARKET CONSENSUS FORECASTS
ACE: 1
Title FY24
Actual
FY25
Actual
FY26
Forecast
FY27
Forecast
EPS (cps) xxx - 2.0 - 2.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 20212022202320242025
EPS Basic xxxxxxxxxxxx-2.0
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx59.4 M
Book Value Per Share xxxxxxxxxxxx33.4
Net Operating Cash Flow xxxxxxxxxxxx8.3 M
Net Profit Margin xxxxxxxxxxxx-4.42 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20212022202320242025
Return on Capital Employed xxxxxxxxxxxx-6.34 %
Return on Invested Capital xxxxxxxxxxxx-5.91 %
Return on Assets xxxxxxxxxxxx-4.29 %
Return on Equity xxxxxxxxxxxx-6.34 %
Return on Total Capital xxxxxxxxxxxx-8.83 %
Free Cash Flow ex dividends xxxxxxxxxxxx-5.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20212022202320242025
Short-Term Debt xxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxx5 M
Total Debt xxxxxxxxxxxx8 M
Goodwill - Gross xxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxx21 M
Price To Book Value xxxxxxxxxxxx2.85

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20212022202320242025
Capex xxxxxxxxxxxx15.5 M
Capex % of Sales xxxxxxxxxxxx26.11 %
Cost of Goods Sold xxxxxxxxxxxx56 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx8 M
Research & Development xxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

27/02/2026

1

Speculative Buy

$2.30

27.78%

Acusensus delivered a strong 1H26 result, with revenue up 40% y.y in line with Morgans, and adjusted EBITDA up 9%, supported by new contract ramp up in New Zealand and Western Australia.

The International segment delivered positive EBITDA of $0.9m for the first time, while operating cash flow was $1.3m and the balance sheet strengthened to $41.0m cash following a $30.0m equity raise and new debt facility.

FY26 revenue guidance and EBITDA were reaffirmed, implying stronger 2H momentum from full run rate contracts and further domestic expansion.

Earnings forecasts are tweaked higher. Speculative Buy retained with a $2.30 target price

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.70 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -3.00 cents.

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

16/02/2026

1

Buy

$2.30

27.78%

Acusensus has announced the settlement of ongoing legal proceedings with Redflex (subsidiary of key global competitor Verra Mobility) in the Australian Federal Court for a total cost of -$16m, payable in $6m cash and $10m scrip at $1.63ps.

As part of the settlement, Acusensus will retain ownership of its existing patent portfolio, however it will need to issue a 'global non-exclusive licence' for any relevant patents to Redflex.

In Canaccord Genuity's view, Acusensus' core competitive advantage is that it combines patented, AI-enabled enforcement technology on a platform that can detect multiple dangerous driving behaviours that is easily scalable to large global government contracts.

The broker therefore remains confident in Acusensus' ability to continue winning work in Australia, with the company currently servicing major enforcement contracts across WA, SA, QLD and NSW, tenders in which VM/Redflex were a likely competitor, in Canaccord's view.

Buy and $2.30 targe retained.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.00 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.10 cents.

ACE STOCK CHART